Delivery Order SPE2DB20D2001-SPE2DB26FPLHY
- Not listed
- The Defense Logistics Agency (DLA) awarded a delivery order to AmerisourceBergen Drug Corp on July 14, 2025, for the supply of Xyosted 100 mg/0.5 mL auto-injector pre-filled syringes valued at $1,716.22. This is a firm fixed price delivery order with an ultimate completion date of July 15, 2025, and represents a non-competitive set-aside award. The performance location is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania. As a child contract, this delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $1,704.88 to AmerisourceBergen Drug Corp for Xyosted 75 mg/0.5 mL auto-injector vials on October 21, 2025, with completion targeted for October 22, 2025. This firm fixed-price delivery order, which carries no set-aside designation, represents a competitively awarded pharmaceutical supply transaction under AmerisourceBergen's broader contract vehicle with the agency. The product will be delivered to the company's corporate office...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on September 22, 2025, for the supply of Xyosted 50 mg/0.5 ml auto-injector pre-filled pens valued at $1,653.41. This is a firm fixed price delivery order with no set-aside designation, reflecting a competitively awarded contract. The place of performance is AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of September 23, 2025. This delivery order represents a...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Xyosted 50 mg/0.5 ml auto-injector units with a ceiling value of $1,314.75 and a completion date of October 23, 2025. This firm fixed-price delivery order represents a non-set-aside competitive award supporting federal medical procurement needs. The contract is performed at the awardee's location in Conshohocken, Pennsylvania, where AmerisourceBergen maintains its corporate...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 26, 2025, for the supply of Xyosted 75 mg/0.5 ml auto-injector units with a ceiling value of $1,346.07. This competitively awarded, non-set-aside contract represents a firm fixed-price delivery order with performance to be completed by August 27, 2025, at the contractor's corporate office location in Conshohocken, Pennsylvania. The contract falls under AmerisourceBergen's larger Indefinite Delivery...
- The Defense Logistics Agency awarded a delivery order valued at $1,090.66 to AmerisourceBergen Drug Corp on September 8, 2025, for the supply of Xyosted 50 mg/0.5 mL auto-injector cartridges. The contract is a firm fixed price delivery order with an ultimate completion date of September 9, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This award was made without a set-aside designation, indicating competitive selection among qualified...
- This delivery order, awarded July 28, 2025, by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, provides Xyosted 100 mg/0.5 mL auto-injector pharmaceutical supplies with a ceiling value of $1,092.55. The contract utilizes firm fixed pricing and is scheduled for completion by July 29, 2025. As a non-set-aside, competitively awarded delivery order, this award represents a continuation of AmerisourceBergen's extensive pharmaceutical supply relationship with DLA. The place of...
- The Defense Logistics Agency awarded a delivery order valued at $4,642.03 to AmerisourceBergen Drug Corp for the supply of Xyosted 75 mg/0.5 mL auto-injector vials. This firm fixed-price, non-set-aside delivery order was awarded on September 24, 2025, with an ultimate completion date of September 25, 2025, and will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. The delivery order represents a continuation of the company's critical role as a...
- The Defense Logistics Agency awarded a delivery order valued at $1,191.17 to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 mL auto-injector units on September 23, 2025, with completion scheduled for September 24, 2025. This competitively awarded, non-set-aside contract utilizes firm fixed pricing and represents a child order under AmerisourceBergen's larger indefinite delivery contract vehicle with DLA Troop Support Medical. The pharmaceutical product will be delivered to the company's...
- The Defense Logistics Agency awarded a $2,858.59 firm fixed-price delivery order to AmerisourceBergen Drug Corp for Xyosted 100 mg/0.5 ml auto-injector pharmaceutical products. This non-set-aside competitive award was issued on September 23, 2025, with an ultimate completion date of September 24, 2025, and will be performed at the contractor's Corporate Office location in Conshohocken, Pennsylvania. The delivery order represents a child contract action under AmerisourceBergen's larger Indefinite...
- SPE2DB20D2001Indefinite Delivery Contract
- SPE2DB20D2001-SPE2DB26FPLHYDelivery Order
The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on October 22, 2025, for the supply of Xyosted 75 mg/0.5 mL auto-injector vials with a ceiling value of $1,150.40. This is a firm fixed-price, competitively awarded delivery order with no set-aside designation and an ultimate completion date of October 23, 2025. The product will be performed at AmerisourceBergen's corporate office location in Conshohocken, Pennsylvania. This delivery order falls under AmerisourceBergen's broader Indefinite Delivery Contract (IDC) with DLA Troop Support Medical, designated SPE2DX, which is valued at $999,999,999.00 and extends through December 2026. AmerisourceBergen Drug Corp is a major pharmaceutical distributor serving as a critical vendor for federal military and veteran healthcare procurement. The company's extensive contract portfolio with the Defense Logistics Agency demonstrates its capability to supply a comprehensive range of pharmaceutical products and medical supplies across multiple therapeutic domains. The Xyosted auto-injector delivery under this order supports the military healthcare supply chain's ongoing need for testosterone replacement therapy products, consistent with AmerisourceBergen's role as a primary pharmaceutical vendor for Department of Defense medical systems.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $1.2k | 10/22/25 |